Serenatis Bio
Serenatis Bio is a forward-thinking biotech company focused on revolutionising the treatment of obsessive-compulsive disorder (OCD) — a mental illness that affects hundreds of millions yet remains under-treated, despite its often devastating impact.
Serenatis Bio is advancing three novel drug candidates targeting OCD, each with unique mechanisms of action, through preclinical development. It is about to complete its pre-seed round of $1.3M, having secured $1.17M from Zinc VC (lead investor), Novaterra Ventures, the Watson Family Office, and P53 Invest. Serenatis is seeking an investor keen to put in the final $130k.
Serenatis Bio will be launching a $30M Series A round in the second half of this year in order to go into clinical trials and would like to speak to investors interested in that round. For more information, please contact Nick Sireau, CEO and Co-founder, on nick@serenatisbio.com
Slide deck (non confidential)
https://biopartnermembers.meeting-mojo.com/uploads/1006/org/20250321-serenatis-bio-full-non-conf-deck-21-march-2025.pdf
Dr Nick Sireau
CEO and Co-founderSilence Therapeutics
Ms Joana Santos
Associate Director, BDMs Marianna Anesti
Head of Business Development, VP
UK Health Security Agency (UKHSA)
Come and talk to us at the UK Pavilion (765) about how we can help support your research and development requirements with consultancy and assay development from our world-renowned experts, our wide range of specialist services and diagnostics, our high containment facilities and our ability to provide high throughput laboratory analysis capacity.
The UK Health Security Agency (UKHSA) is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as globally. We are an executive agency, sponsored by the Department of Health and Social Care
